Skip to main content
SpringerLink
Log in

A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma

  • Brief Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Morton DL, Antman KH, Tepper J: Soft Tissue Sarcoma. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer Medicine, 3rd edition. Lea & Febiger, Philadelphia, 1993, pp 1858–1887

    Google Scholar 

  2. Grever MR, Kopecky KJ, Coltman CA, Files JC, Greenberg BR, Hutton JJ, Talley R, Von Hoff DD, Balcerzak SP: Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30:457–459, 1988

    PubMed  Google Scholar 

  3. Leiby JM, Kraut EH, Metz EN, Malspeis L, Grever MR: Phase II trial of 9-B-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in non-Hodgkin's lymphoma: Prospective comparison of response with deocytidine kinase activity. Cancer Res 47(10):2719–2722, 1987

    PubMed  Google Scholar 

  4. Grever M, Leiby J, Kraut E, Metz E, Neidhart J, Balcerzak S, Malspeis L: A comprehensive phase I and II clinical investigation of fludarabine phosphate. Semin Oncol 17(5):39–48, 1990

    Google Scholar 

  5. Von Hoff D: Phase I clinical trials with fludarabine phosphate. Semin Oncol 17(5):33–38, 1990

    Google Scholar 

  6. Merkel DE, Griffin NL, Kagan-Hallet K, Von Hoff DD: Central nervous system toxicity with fludarabine. Cancer Treat Rep 70(12):1449–1450, 1986

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Cancer Institute, Bethesda, MD, USA

    Micheal R. Grever

  2. Southwest Oncology Group Statistical Center, Seattle, WA, USA

    Jacqueline Benedetti

  3. Ohio State University Health Center, Columbus, OH, USA

    Stanley P. Balcerzak

  4. University of Kansas Medical Center, Kansas City, KS, USA

    Sarah A. Taylor

  5. University of Arizona Cancer Center, Tucson, AZ, USA

    Thomas P. Miller

  6. Wichita CCOP, Wichita, KS, USA

    Shaker R. Dakhil

Authors
  1. Micheal R. Grever
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacqueline Benedetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stanley P. Balcerzak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sarah A. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas P. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shaker R. Dakhil
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grever, M.R., Benedetti, J., Balcerzak, S.P. et al. A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma. Invest New Drugs 12, 259–261 (1994). https://doi.org/10.1007/BF00873969

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00873969

Keywords

Search

Navigation